Demant A/S (OTCMKTS:WILYY) Sees Strong Trading Volume – Should You Buy?

Shares of Demant A/S Unsponsored ADR (OTCMKTS:WILYY) saw an uptick in trading volume on Tuesday . 653 shares were traded during mid-day trading, an increase of 26% from the previous session’s volume of 517 shares.The stock last traded at $21.9875 and had previously closed at $22.50.

Wall Street Analyst Weigh In

WILYY has been the topic of several recent research reports. UBS Group downgraded Demant A/S from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 22nd. Zacks Research upgraded Demant A/S to a “hold” rating in a report on Friday, June 26th. Sanford C. Bernstein downgraded shares of Demant A/S from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 17th. Finally, Morgan Stanley upgraded shares of Demant A/S from an “equal weight” rating to an “overweight” rating in a research report on Tuesday, June 23rd. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy”.

Demant A/S Price Performance

The firm has a 50 day moving average of $21.00 and a 200 day moving average of $17.81. The company has a debt-to-equity ratio of 1.65, a quick ratio of 1.00 and a current ratio of 1.36.

Demant A/S Company Profile

Demant A/S is a Denmark-based global hearing health care company specializing in the development, manufacture and distribution of hearing solutions and audiological diagnostic instruments. The company’s flagship brands include Oticon, Bernafon and Sonic, which offer a range of hearing aids designed to address various levels of hearing loss. In addition to personal hearing devices, Demant provides diagnostic equipment such as audiometers and tympanometers, supporting hearing care professionals in accurate assessment and fitting of hearing solutions.

Beyond hearing aids and diagnostics, Demant’s product portfolio extends to hearing implants—cochlear and bone-anchored systems—through its Oticon Medical division.